Study on Pharmacokinetic Interactions Between HS-10234 and Emtricitabine in Healthy Subjects: An Open-Label, Two-Sequence, Self-Controlled Phase I Trial.
Study on Pharmacokinetic Interactions Between HS-10234 and Emtricitabine in Healthy Subjects: An Open-Label, Two-Sequence, Self-Controlled Phase I Trial.
复制标题
HS-10234与恩曲他滨在健康受试者的药代动力学相互作用研究：一项开放、双序贯、自身对照的I期试验。
DOI：
10.1007/s40121-021-00555-y
复制
发表时间：
2022-03
影响因子：
5.4
通讯作者：
Pei Q
中科院分区：
文献类型：
--
作者：
Luo Y;Chen W;Yang G;Zou C;Huang J;Kuang Y;Shen K;Zhang B;Yang S;Xiang H;Li Z;Pei Q
HS-10234, a novel prodrug of tenofovir (TFV), functions by inhibiting nucleotide reverse transcriptase against retroviral infections including hepatitis B virus and human immunodeficiency virus (HIV). As it is a possible substitute for TFV co-administration with emtricitabine, determining the drug-drug interactions (DDI) between HS-10234 and emtricitabine therapy will be helpful for researchers to design and conduct future phase II/III studies and merits careful examination in the era of evolving new combination antiretroviral therapy regimens. We conducted an open-label, two-sequence, two-period, self-controlled phase I trial that enrolled 36 healthy volunteers randomized into two groups (group 1 and group 2). Eighteen subjects in group 1 were orally administered HS-10234 at a 25-mg daily dose for 7 days during period 1 (D1–D7) followed by co-administration of emtricitabine at a 200-mg dose once daily (QD) for 7 additional days during period 2 (D8–D14). Participants in group 2 were orally administered emtricitabine 200 mg QD for 7 days during period 1 (D1–D7) and then co-administered HS-10234 25 mg QD for 7 additional days during period 2 (D8–D14). Pharmacokinetics (PK) of HS-10234 and emtricitabine were characterized when administered alone and in combination. The concentrations of HS-10234 and its metabolites TFV and emtricitabine were determined using high performance liquid chromatography-mass spectrometry (HPLC-MS)/MS. Peripheral blood monocyte cells (PBMCs) were isolated for detection of intracellular concentrations of HS-10234’s active metabolite, intracellular tenofovir diphosphate (TFV-DP) pre-dose and 2, 4, 8, 12 and 24 h post-dose on D7 and D14 in group 1. WinNonlin software was used to calculate PK parameters. After multiple-dose administration of HS-10234 with emtricitabine, the AUC0–tau of HS-10234 and TFV-DP was 1.327- and 1.403-fold higher than that with HS-10234 administration alone. The Cmax and AUC0–tau were increased 1.120- and 1.077-fold compared to emtricitabine administration alone. Co-administration of HS-10234 with oral emtricitabine was well tolerated. No serious adverse events were observed. Although a slightly increased steady-state PK exposure of HS-10234 and TFV-DP was observed with co-administration of oral HS-10234 with emtricitabine, these changes were not considered clinically relevant. Thus, dose adjustments are not recommended for HS-10234 combination with emtricitabine. NCT04477096, July 20, 2020.
登录
查看更多内容
影响因子：
3.8
作者：
Mocroft, Amanda;Kirk, Ole;Lundgren, Jens D.
通讯作者：
Lundgren, Jens D.
影响因子：
5.9
作者：
Cihlar, Tomas;Fordyce, Marshall
通讯作者：
Fordyce, Marshall
影响因子：
--
作者：
Fuss, Ivan J;Kanof, Marjorie E;Zola, Heddy
通讯作者：
Zola, Heddy
影响因子：
4.9
作者：
Babusis, Darius;Phan, Truc K.;Ray, Adrian S.
通讯作者：
Ray, Adrian S.
影响因子：
25.7
作者：
Agarwal, Kosh;Fung, Scott K.;Foster, Graham R.
通讯作者：
Foster, Graham R.